Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer
|ClinicalTrials.gov Identifier: NCT00897468|
Recruitment Status : Active, not recruiting
First Posted : May 12, 2009
Last Update Posted : May 17, 2017
RATIONALE: Changing the genes in laboratory mice to create a living model of human breast cancer may help doctors learn more about breast cancer.
PURPOSE: This research study is developing mouse models of breast cancer using tissue samples that were previously collected from women with breast cancer.
|Condition or disease||Intervention/treatment|
|Breast Cancer||Other: laboratory biomarker analysis Other: medical chart review|
- To develop new in vivo models of human breast cancer.
- To correlate response in this model to actual treatment outcome in patients, if the in vivo model is proven feasible.
OUTLINE: Previously collected breast tumor fragments are implanted into the renal capsule site of SCID mouse hosts (mouse with severe combined immune deficiency) to establish metastatic spread patterns, and both histologic and molecular tumor characteristics.
Patients' medical charts are reviewed to obtain relevant information, including general demographics, smoking and alcohol use, as well as outcome data such as survival and response to treatment.
|Study Type :||Observational|
|Actual Enrollment :||26 participants|
|Official Title:||Developing In-Vivo Models of Human Breast Cancer|
|Study Start Date :||February 2007|
|Actual Primary Completion Date :||May 15, 2017|
|Estimated Study Completion Date :||March 2018|
|breast cancer patients||
Other: laboratory biomarker analysis
Tissue samples will either be collected at the time of medically indicated surgical procedures or through research core biopsies. A sample of urine will also be obtained. Blood will be collected via venipuncture and lymphocytes (mononuclear cells) separated and processed as a source of normal DNA and normal cells.Other: medical chart review
patient chart review will occur in conjunction with patient data collection for final analyses.
- Development of new in vivo models of human breast cancer [ Time Frame: 1 year ]
- Correlation of response in this model to actual treatment outcome in patients, if the in vivo model proven feasible [ Time Frame: 5 years ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00897468
|United States, Tennessee|
|Vanderbilt-Ingram Cancer Center|
|Nashville, Tennessee, United States, 37232-6838|
|Principal Investigator:||A. Bapsi Chakravarthy, MD||Vanderbilt-Ingram Cancer Center|